Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture. Efavirenz effectively inhibits several wild-type T-lymphoid cell line-adapted variants. Efavirenz also effectively inhibits HIV-1 variants that expressed RT amino acid substitutions which confer the loss of susceptibility to other NNRTIs. Efavirenz is a non-nucleoside analog reverse transcriptase inhibitor (NNRTI) with IC50 of 60 nM.
| Molecular Weight | 315.67 |
| Formula | C14H9ClF3NO2 |
| CAS Number | 154598-52-4 |
| Solubility (25°C) | DMSO ≥ 30 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Reverse Transcriptase Products |
|---|
| Fosalvudine tidoxil
Fosalvudine tidoxil is an orally active nucleoside reverse transcriptase inhibitor (NRTI). |
| Emtricitabine triphosphate tetrasodium salt
Emtricitabine triphosphate tetrasodium salt is the tetrasodium salt form of Emtricitabine triphosphate and a nucleoside reverse transcriptase inhibitor (NRTI) targeting HIV and HBV. |
| M-MLV Reverse transcriptase
M-MLV Reverse transcriptase (M-MLV RT) is a kind of Reverse transcriptase, from the moroni mouse leukemia virus (MoMLV). |
| ddUTP
ddUTP (2′,3′-Dideoxyuridine-5′-triphosphate) is a selective HIV and AMV reverse transcriptase inhibitor with Ki values of 0.05 µM and 1 µM, respectively. |
| Rovafovir etalafenamide
Rovafovir etalafenamide (GS-9131), a proagent of the adenosine nucleotide analogue GS-9148, is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Rovafovir etalafenamide is potent and active against a variety of NRTI mutants, and shows potent anti-HIV-1 activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
